EP4478887A4 - Neue pharmazeutische zusammensetzungen und verfahren zur behandlung von schlaflosigkeit - Google Patents

Neue pharmazeutische zusammensetzungen und verfahren zur behandlung von schlaflosigkeit

Info

Publication number
EP4478887A4
EP4478887A4 EP22927519.3A EP22927519A EP4478887A4 EP 4478887 A4 EP4478887 A4 EP 4478887A4 EP 22927519 A EP22927519 A EP 22927519A EP 4478887 A4 EP4478887 A4 EP 4478887A4
Authority
EP
European Patent Office
Prior art keywords
installation
treatment
methods
pharmaceutical compositions
new pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22927519.3A
Other languages
English (en)
French (fr)
Other versions
EP4478887A1 (de
Inventor
Jianmin Wang
fengyuan Jia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LA PharmaTech Inc
Original Assignee
LA PharmaTech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LA PharmaTech Inc filed Critical LA PharmaTech Inc
Publication of EP4478887A1 publication Critical patent/EP4478887A1/de
Publication of EP4478887A4 publication Critical patent/EP4478887A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP22927519.3A 2022-02-16 2022-02-16 Neue pharmazeutische zusammensetzungen und verfahren zur behandlung von schlaflosigkeit Pending EP4478887A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2022/016545 WO2023158424A1 (en) 2022-02-16 2022-02-16 Novel pharmaceutical compositions and methods for treatment of insomnia

Publications (2)

Publication Number Publication Date
EP4478887A1 EP4478887A1 (de) 2024-12-25
EP4478887A4 true EP4478887A4 (de) 2026-01-28

Family

ID=87578930

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22927519.3A Pending EP4478887A4 (de) 2022-02-16 2022-02-16 Neue pharmazeutische zusammensetzungen und verfahren zur behandlung von schlaflosigkeit

Country Status (4)

Country Link
EP (1) EP4478887A4 (de)
JP (1) JP2025526852A (de)
CN (1) CN119012916A (de)
WO (1) WO2023158424A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120083479A1 (en) * 2004-11-24 2012-04-05 Meda Pharmaceuticals Inc. Compositions Comprising Azelastine and Methods of Use Thereof
US20160166543A1 (en) * 2014-12-10 2016-06-16 Hemant N. Joshi Stable combination oral liquid formulation of melatonin and an antihistaminic agent

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
JP4613031B2 (ja) * 2004-05-06 2011-01-12 エスエス製薬株式会社 催眠剤組成物
DK2486942T3 (en) * 2004-11-24 2019-01-28 Meda Pharmaceuticals Inc COMPOSITIONS CONTAINING AZELASTINE AND PROCEDURES FOR USING IT
JP2010195716A (ja) * 2009-02-25 2010-09-09 Takeda Chem Ind Ltd 点鼻睡眠導入剤
CA2803382C (en) * 2010-07-02 2015-03-31 The Procter & Gamble Company Method for delivering an active agent
AU2019443520A1 (en) * 2019-04-30 2021-12-23 La Pharma Tech Inc. A method of treating mental, behavioral, cognitive disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120083479A1 (en) * 2004-11-24 2012-04-05 Meda Pharmaceuticals Inc. Compositions Comprising Azelastine and Methods of Use Thereof
US20160166543A1 (en) * 2014-12-10 2016-06-16 Hemant N. Joshi Stable combination oral liquid formulation of melatonin and an antihistaminic agent

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "AZELASTINE HYDROCHLORIDE TABLETS 1mg "TOWA" | Kusuri-no-Shiori(Drug Information Sheet)", 1 December 2017 (2017-12-01), pages 1 - 2, XP093343997, Retrieved from the Internet <URL:https://www.rad-ar.or.jp/siori/english/search/result?n=39759> [retrieved on 20251204] *
See also references of WO2023158424A1 *
STORMS W W: "Pharmacologic approaches to daytime and nighttime symptoms of allergic rhinitis", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 114, no. 5, 1 November 2004 (2004-11-01), pages S146 - S153, XP004621143, ISSN: 0091-6749, DOI: 10.1016/J.JACI.2004.08.045 *

Also Published As

Publication number Publication date
JP2025526852A (ja) 2025-08-15
EP4478887A1 (de) 2024-12-25
CN119012916A (zh) 2024-11-22
WO2023158424A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
EP4281464A4 (de) Zusammensetzungen und verfahren zur behandlung von stoffwechsel- und lebererkrankungen
EP4373939A4 (de) Genomeditierungszusammensetzungen und verfahren zur behandlung von chronischer granulomatöser erkrankung
EP4415755A4 (de) Ace2-gerichtete zusammensetzungen und verfahren zur behandlung von covid-19
EP4401792A4 (de) Zusammensetzungen und verfahren zur behandlung von fazioskapulohumeraler muskeldystrophie
EP4203990A4 (de) Verfahren und zusammensetzungen zur behandlung von glioblastom
EP4165025A4 (de) Zusammensetzungen und verfahren zur behandlung und prävention von neurologischen erkrankungen
EP4413137A4 (de) Zusammensetzungen und verfahren zur behandlung von cag-wiederholungserkrankungen
EP4499625A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP4188346A4 (de) Nobiletinzusammensetzungen und verfahren zur behandlung und prävention von covid-19 und verwandten erkrankungen
EP4340860A4 (de) Zusammensetzungen und verfahren zur behandlung von neuropathie
EP4114411A4 (de) Zusammensetzungen und verfahren zur behandlung von bauchspeicheldrüsenkrebs
EP4419144A4 (de) Zusammensetzungen und verfahren zur behandlung von muskeldystrophie
EP4228696A4 (de) Zusammensetzungen und verfahren zur behandlung von bluterkrankungen
EP4114438A4 (de) Verfahren und zusammensetzungen zur behandlung von muskelatrophie
EP4551220A4 (de) Pharmazeutische zusammensetzungen und verfahren zur behandlung von schlaflosigkeit
EP4326757A4 (de) Neue zusammensetzungen und verfahren zur behandlung von coronavirus-infektionen
EP4561557A4 (de) Zusammensetzungen und verfahren zur behandlung von stoffwechselerkrankungen
EP4456890A4 (de) Zusammensetzungen und verfahren zur behandlung von lungenerkrankungen
EP4408532A4 (de) Zusammensetzungen und verfahren zur behandlung von pcdh19-bedingten erkrankungen
EP4413136A4 (de) Zusammensetzungen und verfahren zur behandlung von prionenkrankheiten
EP4469559A4 (de) Zusammensetzungen und verfahren zur behandlung von mesothelinpositiven krebsarten
EP4340897A4 (de) Verfahren und zusammensetzungen zur behandlung von pankreas- und lebererkrankungen
EP4412632A4 (de) Zusammensetzungen und verfahren zur behandlung von stoffwechselerkrankungen
EP4340835A4 (de) Verfahren und zusammensetzungen zur behandlung von herz-kreislauf-erkrankungen
EP4237094A4 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung davon zur behandlung von krebs

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20241007

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20260102

RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 57/00 20060101AFI20251219BHEP

Ipc: A61K 31/67 20060101ALI20251219BHEP

Ipc: A61K 31/4045 20060101ALI20251219BHEP

Ipc: A61K 31/55 20060101ALI20251219BHEP